Chemoradiation therapy for cervical cancer: Toxicity of concurrent weekly cisplatin

被引：36

作者：

Ikushima H. ^{[1
,4
]}

Osaki K. ^{[1
]}

Furutani S. ^{[1
]}

Yamashita K. ^{[1
]}

Kawanaka T. ^{[1
]}

Kishida Y. ^{[1
]}

Iwamoto S. ^{[1
]}

Takegawa Y. ^{[2
]}

Kudoh T. ^{[3
]}

Nishitani H. ^{[1
]}

机构：

[1] Department of Radiology, Tokushima University School of Medicine, Tokushima

[2] Department of Health Sciences, Tokushima University School of Medicine, Tokushima

[3] Department of Oral and Maxillofacial Radiology, Tokushima University School of Medicine, Tokushima

[4] Department of Radiology, Tokushima University School of Medicine, Tokushima 770-8503

来源：

Radiation Medicine | 2006年 / 24卷 / 2期

关键词：

Acute toxicity; Cervical cancer; Concurrent chemotherapy; Radiation therapy;

D O I：

10.1007/BF02493277

中图分类号：

学科分类号：

摘要：

Purpose: To retrospectively evaluate the toxicity of concurrent weekly cisplatin and radiation therapy (RT) for locally advanced cervical cancer. Materials and Methods: Between April 2001 and December 2004, 21 consecutive previously untreated patients with locally advanced cervical cancer were treated with concurrent chemoradiation therapy (CCRT) at the Tokushima University Hospital. Clinical stages were II: 5, III: 15, IVA: 1. External beam radiation therapy (EBRT) was delivered with 10 MV X-rays, 2 Gy fraction per day; total dose to the whole pelvis was 50 Gy. Iridium-192 high-dose-rate (HDR) intracavitary radiation therapy was performed with 10-30 Gy (median, 24 Gy) targeted at point A. Concurrent chemotherapy consisted of cisplatin, administered weekly at a dose of 40 mg/m2 for patients who were younger than 65 years and 30 mg/m2 for those 65 years or over. A maximum single dose of cisplatin, up to 70 mg/body, was administered in 5 cycles during EBRT. Results: A total of 86 cycles of cisplatin were administered to the 21 patients, with a median of 4 cycles (range, 2-5). Severe hematological toxicity occurred in 18 patients (86%), including grade 3 in 17 patients (81%) and grade 4 in one patient (4.8%). Moderate or severe gastrointestinal toxicity occurred in 11 patients (52%), including grade 2 in 10 patients (48%) and grade 3 in one patient (4.8%). The grades of hematological toxicity were significantly greater in the 40 mg/m2 group than in the 30 mg/m2 group. All of the patients who were administered 40 mg/m2 of cisplatin developed grade 3 or greater hematological toxicity, including one patient with grade 4 toxicity. In the 30 mg/m2 group, 3 of 10 patients developed less than grade 3 toxicity, and all patients completed radiation therapy without interruption. Conclusion: The incidence of severe acute hematological toxicity was significantly higher in this study than in previously reported randomized controlled trials (RCTs), especially in the group of 40 mg/m2 cisplatin. A dose of 30 mg/m2 of cisplatin was considered to be feasible in weekly cisplatin and radiation therapy.

引用

页码：115 / 121

页数：6

共 16 条

[1]

Morris M., Eifel P.J., Lu J., Et al., Pelvic radiation with concurrent chemotherapy compared with pelvic and paraaortic radiation for high-risk cervical cancer, N Engl J Med, 340, pp. 1137-1143, (1999)

[2]

Rose P.G., Bundy B.N., Watkins E.B., Et al., Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer, N Engl J Med, 340, pp. 1144-1153, (1999)

[3]

Keys H.M., Bundy B.N., Stehman F.B., Et al., Cisplatin, radiation and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma, N Engl J Med, 340, pp. 1154-1161, (1999)

[4]

Whitney C.W., Sause W., Bundy B.N., Et al., Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: A Gynecologic Oncology Group and Southwest Oncology Group study, J Clin Oncol, 17, pp. 1339-1348, (1999)

[5]

Peters II W.A., Liu P.Y., Barrett II R.J., Et al., Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix, J Clin Oncol, 18, pp. 1606-1613, (2000)

[6]

Shepherd J.H., Staging announcement: FIGO staging of gynecologic cancers. Cervical and vulva, Int J Gynecol Cancer, 5, (1995)

[7]

Tod M.C., Meredith W.J., A dosage system for use in the treatment of cancer of uterine cervix, Brit J Radiol, 11, pp. 809-817, (1938)

[8]

Common Toxicity Criteria, (1988)

[9]

Cox J.D., Stetz J., Pajak T.F., Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC), Int J Radiat Oncol Biol Phys, 31, pp. 1341-1346, (1995)

[10]

Green J.A., Kirwan J.M., Tierney J.F., Et al., Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: A systematic review and meta-analysis, Lancet, 358, pp. 781-786, (2001)

← 1 2 →